Home / Companies / Janux Therapeutics, Inc. / 11 Jun 2026
Janux Therapeutics, Inc.: meeting of 11 Jun 2026
Votes reported on Form N-PX, item by item
299 Form N-PX filers reported votes at the Janux Therapeutics, Inc. meeting of 11 Jun 2026. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
2 nominees; 79.9% of reported votes for; 42 filers withheld from or voted against at least one nominee.
366 vote records from 96 filers. 3 of the 96 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
435 vote records from 298 filers. 78 of the 281 filers that marked the item either way voted against management. 17 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
183 vote records from 96 filers. 1 of the 96 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | For | For | For |
| Fidelity | For | For | For |
| Dimensional | Abstain or withhold * | Against * | For |
| State Street and SPDR | For | For | For |
| American Century | Split or no vote | Against * | For |
| Franklin Templeton | For | For | For |
| Invesco | For | Against * | For |
| Equitable | For | For | For |
| Charles Schwab | For | For | For |
| Nuveen and TIAA | For | For | For |
| ProShares and ProFunds | Split or no vote | For | For |
| John Hancock and Manulife | Split or no vote | For | For |
| Morgan Stanley, Eaton Vance and Calvert | Split or no vote | Against * | For |
| J.P. Morgan | For | For | For |
| Goldman Sachs | For | For | For |
| PGIM and Prudential | Abstain or withhold * | Against * | For |
| Jackson National funds | For | For | For |
| Northern Trust and FlexShares | Split or no vote | For | For |
| SEI | For | Against * | For |
| T. Rowe Price | For | For | For |
| Lincoln Financial | For | For | For |
| Voya | Split or no vote | For | For |
| First Trust | No report | For | No report |
| Russell Investments | No report | Against * | No report |
| Nationwide | For | Against * | For |
| Victory Capital | Split or no vote | For | For |
| Brighthouse Funds | Split or no vote | For | For |
| Guggenheim and Rydex | Split or no vote | For | For |
| Columbia Threadneedle | For | For | For |
| BNY Mellon | No report | For | No report |
| Principal | Split or no vote | For | For |
| Pacific Life funds | For | For | For |
| Global X | For | Against * | For |
| Federated Hermes | Split or no vote | Against * | For |
| AllianceBernstein | No report | For | No report |
| Hartford Funds | For | Against * | For |
| DWS | Split or no vote | For | For |
| Allspring | Split or no vote | For | For |
| Macquarie and Delaware Funds | Split or no vote | For | For |
| Janus Henderson | For | For | For |
| Neuberger Berman | No report | Against * | No report |
| Natixis and Loomis Sayles | No report | Against * | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Janux Therapeutics, Inc. meeting?
299 Form N-PX filers reported votes at the meeting of 11 Jun 2026. On say-on-pay, 78 of 281 voted against management (27.8%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Janux Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Janux Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Janux Therapeutics, Inc. with a meeting date within three days of 11 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.